The PSD95-nNOSinhibitor also suppresses morphine-induced dopamine efflux in the nucleus accumbens shell.Collectively, our results demonstrate that disrupting PSD95-nNOS protein-proteininteractions is effective in attenuating pathological pain without producing unwanted sideeffects (i.e. motor ataxia, reward) associated with NMDAR antagonists. The gene discussed is DLG4; the disease is Ataxia.